| Project/Area Number |
25462754
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Hirokazu Sakaguchi 大阪大学, 医学(系)研究科(研究院), 寄附講座准教授 (80379172)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIDA KOHJI 大阪大学, 医学系研究科, 教授 (40244610)
HAYASHI RYUHEI 大阪大学, 医学系研究科, 寄附講座准教授 (70535278)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | 網膜疾患 / 硝子体投与 / DDS / 自己集合性ペプチド / 自己集合性ペプチドゲル / 硝子体内投与 |
|---|
| Outline of Final Research Achievements |
When treating a disease pharmacologically, it is most effective to deliver a drug directly to the affected area. In retinal disease, intravitreal administration has been widely used and, often needed frequent dosing because the duration of effect of drug is short. Therefore it’s imperative that controlled release agent remaining effective for a long time is developed. We confirmed that a self-assembling peptide had an ability to release a drug slowly and the released drug had effect. Additionally, we checked that the controlled release agent could be administered intravitreally.
|
